Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Impact of CYP2D6 Polymorphism on Tramadol Pharmacodynamics
Sponsor: Elweyia Maternity Teaching Hospital
Summary
CYP2D6 is an enzyme involved in the hepatic metabolism of many clinically important drugs: antiarrhythmics, antidepressants, antipsychotics, β-blockers, and analgesics such as tramadol and codeine. CYP2D6 is highly polymorphic and significant interindividual variability has been observed worldwide. This study aims to investigate the distribution of CYP2D6 polymorphisms among post-cesarean female patients in Erbil city, Iraq. The findings of this study may indicate the presence of CYP2D6 gene variants among the Kurdish female population in Erbil, which could contribute to tramadol analgesic failure or exaggerated adverse effects. This study could also serve as a foundation for further pharmacogenetic research, individualizing treatments and targeting a larger sample size in the future.
Official title: The Outcome of CYP2D6 Polymorphism on Tramadol Analgesia in Postpartum Patients in Erbil
Key Details
Gender
FEMALE
Age Range
18 Years - 50 Years
Study Type
OBSERVATIONAL
Enrollment
40
Start Date
2024-09-22
Completion Date
2025-03-31
Last Updated
2025-02-07
Healthy Volunteers
No
Interventions
Trodon® Hemofarm
Consent was taken from each patient prior to the enrollment into the study during the first interview and 2 ml of blood was withdrawal for the CYP2D6 genotyping. After the cesarean section surgery, each patient received one dose of 100mg/2ml Trodon® Hemofarm for treating the postpartum pain and the patients were monitored for 24 hours. Follow-up was performed for each enrolled patient in which the VAS score, blood pressure, heart rate, oxygen saturation and any new effects after 1 hour, 6 hours of tramadol administration were recorded. In addition, after 24 hours evaluations for nocturnal pain, dietary state and bowel movement were performed.
Locations (1)
Hawler Medical University/ College of Medicine
Erbil, Iraq